New Drug Reviews

Vilazodone (Viibryd) for the Treatment of Depression


Am Fam Physician. 2013 Aug 15;88(4):263-264.

Vilazodone (Viibryd) is a serotonin1A partial agonist and reuptake inhibitor labeled for the treatment of major depressive disorder in adults.

 Enlarge     Print

DrugDosageDose formCost of one month of treatment*

Vilazodone (Viibryd)

10 mg per day, increasing over two weeks to 40 mg per day

10-, 20-, and 40-mg tablets

$149 for 30 tablets (prices are identical for 10-, 20-, and 40-mg tablets)

*—Estimated retail price of one month's treatment based on information obtained at (July 11, 2013).

DrugDosageDose formCost of one month of treatment*

Vilazodone (Viibryd)

10 mg per day, increasing over two weeks to 40 mg per day

10-, 20-, and 40-mg tablets

$149 for 30 tablets (prices are identical for 10-, 20-, and 40-mg tablets)

*—Estimated retail price of one month's treatment based on information obtained at (July 11, 2013).


Vilazodone causes few serious adverse effects, although long-term safety has not been established.1 In a one-year open-label case series, 3.8% of patients experienced serious adverse effects, including pneumonia, suicidal ideation or behavior, and serotonin syndrome.1 As with other antidepressants, vilazodone carries a boxed warning for increased risk of suicidality in patients 24 years and younger.2 Vilazodone is contraindicated in patients taking monoamine oxidase inhibitors, and its use should be avoided with other serotonergic drugs, including antidepressants, tramadol (Ultram), and triptans.2 Vilazodone does not cause electrocardiographic changes or significant abnormal findings on basic laboratory tests.14 Strong inhibitors of the cytochrome P450 3A4 liver enzyme, such as ketoconazole, may cause excessive accumulation of vilazodone; therefore, the dosage of vilazodone should be reduced to 20 mg per day when used concurrently with these types of medications.2,5


About one in 14 patients taking vilazodone for eight weeks will discontinue the medication because of unwanted effects, which is about twice as common as in patients taking placebo.24 The most common adverse effects are nausea and diarrhea, although these are usually transient.24 Less commonly, vilazodone may cause dizziness, insomnia, vomiting, abnormal dreams, akathisia, palpitations, tremor, and paresthesias.24 Vilazodone causes sexual dysfunction in about 16% of men and 5% of women.24 Patients can expect to gain about 3.8 lb (1.7 kg) after 12 months.1


Vilazodone has not been studied in patients who have mild to moderate major depression. It has been studied in patients with moderate to severe depression, with investigators looking at clinical remission and treatment response (characterized as a 50% or greater reduction in depression score). Among outpatients with moderate to severe depression, vilazodone will induce clinical remission in about 25% of patients compared with 18% taking placebo,24 with one additional patient achieving relief after eight weeks for every 14 patients treated with vilazodone compared with placebo (number needed to treat [NNT] = 14; 95% confidence interval [CI], 8 to 55).24 Similarly, about 42% of patients who have moderate to severe depression will respond to treatment (NNT = 8; 95% CI, 6 to 16).24 To date, no research has been conducted to determine the rate of relapse in patients taking vilazodone. There are no studies comparing vilazodone with other depression treatments.


A one-month supply of vilazodone (40 mg per day) costs approximately $149.6 In comparison, a 90-day supply of amitriptyline (50 mg per day) costs approximately $10, and a 90-day supply of sertraline (Zoloft; 100 mg per day) costs approximately $17.6


Vilazodone should be taken once daily in the morning with food to increase absorption.7 The starting dosage is 10 mg per day and is titrated upward over two weeks to a target dosage of 40 mg per day.7 Patients should be instructed to taper the dosage when discontinuing use.7

Bottom Line

The available evidence does not support the routine use of vilazodone in the treatment of depression. It is significantly more expensive than generic alternatives and is no more effective for moderate to severe depression than selective serotonin reuptake inhibitors or tricyclic antidepressants.8 Furthermore, vilazodone has not been studied in the treatment of mild to moderate depression, the kind most commonly seen by family physicians. Although vilazodone appears to be safe for long-term use based on a small study of one year's duration, other antidepressants have much more research supporting their long-term safety.

Address correspondence to John D. Gazewood, MD, MSPH, at Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.


show all references

1. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(5):643–646....

2. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356–368.

3. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441–447.

4. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressivedisorder : arandomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–333.

5. Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry. 2011;72(9):1166–1173.

6. Accessed July 11, 2013.

7. Choi E, Zmarlicka M, Ehret MJ. Vilazodone: a novel anti-depressant. Am J Health Syst Pharm. 2012;69(18):1551–1557.

8. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009(3):CD007954.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series coordinator for AFP is Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Mass.

A collection of STEPS published in AFP is available at



Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article